8A-PDHQ

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Tom.Reding (talk | contribs) at 14:18, 17 May 2016 (→‎top: Enumerate multiple authors/editors (CS1 maintenance) using AWB). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

8A-PDHQ
Identifiers
  • 8a-phenyldecahydroquinoline
CAS Number
PubChem CID
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC15H21N
Molar mass215.3339 g/mol g·mol−1
3D model (JSmol)
  • C1([C@]23CCCC[C@H]2CCCN3)=CC=CC=C1
  • InChI=1S/C15H21N/c1-2-7-13(8-3-1)15-11-5-4-9-14(15)10-6-12-16-15/h1-3,7-8,14,16H,4-6,9-12H2 checkY
  • Key:QEXADSRMRUUCQJ-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

8a-Phenyldecahydroquinoline (8A-PDHQ) is a high affinity NMDA antagonist developed by a team at Parke Davis in the 1950s.[1] It is a structural analog of Phencyclidine with slightly lower binding affinity than the parent compound. (-)-8a-Phenyldecahydroquinoline has an in vivo potency comparable to that of (+)-MK-801.[2][3]

References

  1. ^ US Patent 3035059
  2. ^ Chen C; Kozikowski AP; Wood PL; Reynolds IJ; Ball RG; Pang YP (1992). "Synthesis and biological activity of 8a-phenyldecahydroquinolines as probes of PCP's binding conformation. A new PCP-like compound with increased in vivo potency". Journal of Medicinal Chemistry. 35 (9): 1634–8. doi:10.1021/jm00087a020. PMID 1315871.
  3. ^ Elhallaoui M; Laguerre M; Carpy A; Ouazzani FC (2002). "Molecular modeling of noncompetitive antagonists of the NMDA receptor: proposal of a pharmacophore and a description of the interaction mode". J Mol Model. 8 (2): 65–72. doi:10.1007/s00894-001-0067-4. PMID 12032600.